A carregar...
Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study
PURPOSE: Patients with severe asthma are eligible for asthma-specific biologics as add-on therapies, such as mepolizumab and omalizumab, when optimized controller therapies are unable to control their symptoms. However, few real-world data are available to describe the characteristics and associated...
Na minha lista:
| Publicado no: | J Asthma Allergy |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6354698/ https://ncbi.nlm.nih.gov/pubmed/30774390 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JAA.S189676 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|